Stock IONS IONIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-06 pm EDT 		5-day change 1st Jan Change
42.28 USD +0.74% Intraday chart for Ionis Pharmaceuticals, Inc. +0.69% -16.43%
02:20pm Ionis Pharmaceuticals Q1 Net Loss Widens as Revenue Falls MT
01:53pm Earnings Flash (IONS) IONIS PHARMACEUTICALS Posts Q1 Revenue $119M MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ionis Pharmaceuticals Q1 Net Loss Widens as Revenue Falls
MT
Earnings Flash (IONS) IONIS PHARMACEUTICALS Posts Q1 Revenue $119M
MT
Ionis Pharmaceuticals: Q1 Earnings Snapshot
AQ
Ionis reports first quarter 2024 financial results
PR
Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024
CI
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Ionis Publishes 2023 Corporate Responsibility Report
PR
Ionis to hold first quarter 2024 financial results webcast
PR
North American Morning Briefing : Stock Futures -2-
DJ
Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform
MT
North American Morning Briefing : Traders Await -2-
DJ
Oppenheimer Raises Ionis Pharmaceuticals' Price Target to $75 From $72, Maintains Outperform Rating
MT
Ionis Pharmaceuticals : Listen to webcast
PU
Transcript : Ionis Pharmaceuticals, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 03:00 PM
Transcript : Ionis Pharmaceuticals, Inc. - Special Call
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
AQ
Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome
CI
Ionis to present at upcoming investor conferences
PR
Ionis Pharmaceuticals - Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology annual meeting
AQ
Transcript : Ionis Pharmaceuticals, Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-20-2024 10:30 AM
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IONS Stock
  4. News Ionis Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW